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Abstract 
An attractive strategy for ameliorating symptoms arising from the multi-faceted processes of 
excessive and/or continual inflammation would be to identify compounds able to interfere 
with multiple effectors of inflammation. The well-tolerated pharmaceutical, heparin, is 
capable of acting through several proteins in the inflammatory cascade, but its use is 
prevented by strong anticoagulant activity. Derivatives of heparin involving the periodate 
cleavage of 2,3 vicinal diols in non-sulfated uronate residues (glycol-split) and replacement 
of N-sulphamido- with N-acetamido- groups in glucosamine residues, capable of inhibiting 
neutrophil elastase activity in vitro, while exhibiting attenuated anticoagulant properties, have 
been identified and characterised. These also interact with two other important modulators of 
the inflammatory response, IL-8 and TNF-alpha. It is therefore feasible in principle to 
modulate several activities, while minimising anticoagulant side effects, providing a platform 
from which improved anti-inflammatory agents might be developed. 
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1. Introduction  
Inflammation is the result of the biological response to injury or harmful stimuli, e.g. irritants, 
pathogens or damaged cells, in an attempt by the organism to defend and heal itself. The 
inflammatory response involves a complex network of cellular changes, cytokine release and 
cellular infiltration. Neutrophils play an important role in host defence against fungal and 
bacterial infections. They are primed, activated and engaged in bacterial phagocytosis 
releasing large amounts of oxidants and intracellular stored proteases, which include 
neutrophil elastase (NE) and matrix metalloprotease-9 (MMP-9) (Downey, Bell, & Elborn, 
2009). Recently, recognition of NE as a promising therapeutic target in chronic inflammatory 
diseases has increased (Mitsuhashi et al., 1999; Yoshimura et al., 2003). The imbalance 
between NE and its inhibitors is implicated in many inflammatory diseases, including 
rheumatoid arthritis, respiratory distress syndrome, pulmonary emphysema and acute lung 
injury. Their importance in inflammation can be seen, for example, in cystic fibrosis (CF) 
patients, who suffer continual bacterial infection. Interleukin-8 (IL-8) is responsible for 
neutrophil recruitment to sites of infection, contributes to neutrophil transendothelial 
migration into CF airways and its expression is prolonged following bacterial, e.g. 
Pseudomonas aeruginosa, stimulation (Joseph, Look, & Ferkol, 2005). This results in 
excessive cellular recruitment, further triggering the release of pro-inflammatory mediators 
and chemoattractants (Cosgrove, Chotirmall, Greene, & McElvaney, 2011; Wilmott, Frenzke, 
Kociela, & Peng, 1994). Among the released proteases, NE has the most potential to cause 
undesired tissue injury (Suzuki et al., 1996) by escaping from cells and degrading structural 
proteins, such as elastin and fibronectin, while interfering with the innate airway immunity by 
impairing opsonophagocytosis (Tosi, Zakem, & Berger, 1990). 
 
Another cytokine, TNF-alpha (TNFα), lying at a node in networks of interactions in the 
inflammatory pathways of many diseases, is involved in the promotion of macrophage 
transformation to T-helper cells and neutrophil activation. One possible route to the 
suppression of excessive inflammation could be the targeting of multiple activities, for 
example, the inhibition of NE activity and the sequestering of interleukins of central 
importance to neutrophil activation, such as IL-8 and TNFα. 
 
Heparin, the polydisperse, heterogeneous, linear sulfated polysaccharide, which is used 
widely in the clinic as an antithrombotic agent and is generally well tolerated, interacts with 
and inhibits the activity of many regulatory proteins (Ori, Wilkinson, & Fernig, 2008; Ori, 
Wilkinson, & Fernig, 2011) including IL-8 and elastase. Furthermore, heparin has been 
shown capable of modulating growth factor receptor binding and activity (Jayson & 
Gallagher, 1997), inhibiting the enzyme heparanase (Brown, Lever, Jones, & Page, 2003; 
Lever & Page, 2002; Vlodavsky et al., 1994) and reducing selectin-mediated interactions 
(Borsig et al., 2001; Varki & Varki, 2002). It has been suggested that heparin may have the 
potential to relieve symptoms in lung conditions, ranging from the excess of NE in CF 
airways to asthma (Diamant et al., 1996) or even respiratory distress syndrome. 
Nevertheless, although several studies reported that heparin did not cause bleeding (Yip, 
Lim, & Chan, 2011) the effective dose of heparin (or low molecular weight heparin) required 
to achieve prolonged anti-inflammatory effects could result in anticoagulant complications. 
 
A solution to the problem of anticoagulant side-effects may be offered by chemically 
modified derivatives of heparin, which retain the desired activities, but exhibit attenuated 
anticoagulant activity (Lever & Page, 2002). Many such derivatives have been studied and 
characterised (Mulloy, Forster, Jones, & Davies, 1993; Rudd et al., 2009; Yates et al., 1996) 
and some of their activities, such as angiogenesis inhibition (Casu et al., 2004), 
antimetastatic activity and antagonism of P-selectins (Hostettler et al., 2007), have been 
reported. Heparin and its derivatives serve as proxies for the naturally occurring GAG, 
heparan sulfate (HS), known to interact with hundreds of proteins, many of them involved in 
regulation of the extracellular matrix (Ori et al., 2008, 2011). The chemical modification of 
heparin, especially de-O- and de-N-sulfation, which usually results in a net reduction of the 
overall charge density and also tend to reduce structural complexity, provides the means by 
which biochemical processes can be influenced, while attenuating undesired anticoagulant 
activities. 
 
Since NE (Fryer et al., 1997; Redini et al., 1988; Walsh, Dillon, Scicchitano, & McLennan, 
1991) and IL-8 (Goger et al., 2002) have been identified as relevant to chronic inflammatory 
conditions and interact with HS, the ability of a series of chemically modified heparin 
derivatives to exhibit a combination of favourable activities in vitro was explored. The aim 
was to generate a series of compounds able to inhibit NE and to bind to key modulators of 
the inflammatory network, IL-8 and TNF-, while exhibiting severely attenuated potential side-
effects, particularly anticoagulant activity (AT/factor Xa, PT and APTT). 
 
2. Methods  
2.1. Preparation and characterisation of heparin derivatives  
The N-acetylated heparin and glycol-split derivatives were prepared as described previously 
(Casu et al., 2004; Naggi et al., 2005) starting from unmodified pig mucosal heparin (PMH 
compound 1, Bioiberica S.A., Spain) and characterised by 13C NMR (see Supplementary 
data). The weight average molecular weights (Mw) were determined in sodium nitrate at a 
concentration of 5 mg/mL and at 313K employing Viscotek HP-SEC–TDA (Table 1) 
equipped with a SEC column coupled with three detectors, light scattering, refractometer 
and viscosimeter (Bertini, Bisio, Torri, Bensi, & Terbojevich, 2005). 
 
 
Table 1 Structural characteristics of the compounds originating from heparin (series A; 1–1c) and glycol-
split heparin (series B; 2–2d) derivatives. The table contains the materials weight average molecular 
weight (Mw), percentage of N-acetyl substitution in glucosamine residues and percentage of glycol-split 
uronate residues (cleavage by periodate oxidation of vicinal diols in unsubstituted d-GlcA and l-IdoA 
residues). Compound 1 is unmodified PMH, used as reference for series A, while compound 2 is glycol-
split heparin, used as reference for series B. 
Series Compound Mw (kDa) % N-acetyl % Glycol-split 
A 1 (PMH) 20.0 15 0 
 1a 21.0 45 0 
 1b 22.0 64 0 
 1c 17.0 100 0 
B 2 16.5 15 20 
 2a 17.0 27 27 
 2b 13.0 49 35 
 2c 15.0 64 25 
 2d 16.0 100 25 
 
 
2.2. Anticoagulant assay  
The anticoagulant activity of the derivatives was assayed using the COATEST® heparin 
(chromogenix) following the manufacturer’s instructions. Briefly, heparin reacts with 
antithrombin and an excess of factor Xa was added leading to the formation of a ternary 
complex. Free factor Xa cleaves a chromogenic substrate and the absorbance is read at 405 
nm. Several concentrations of standard heparin were tested and a standard curve was 
obtained from 0 to 0.35 μg/mL. Then, the heparin derivatives (0.25 μg/mL) were tested and 
compared to the same concentration of standard heparin. The test was performed twice in 
duplicate in a 96-well plate and the colour read photometrically (VersaMaxmicroplate reader, 
Molecular Devices, USA). 
 
The PT assay was performed as per the manufacturer’s instructions with some minor 
modifications. Pooled (normal) human plasma was obtained from Technoclone Ltd (UK). 
Briefly, the test sample was incubated with plasma prior to the addition of Thromborel S 
(Siemens, at 2X concentration). The time taken for clot formation was monitored using a 
thrombotic coagulometer (Stage Diagnostics) and recorded if the clot formation occurred 
before 120 s. 
 
APTT assays were performed essentially according to the manufacturer’s instructions. 
Briefly, human plasma test sample and Pathromtin SL (Siemens) were incubated for 2 min at 
37 ◦C, 50 mM CaCl2 was then added to initiate coagulation. The time taken for clot 
formation was observed as per PT assay. 
 
2.3. Competitive ELISA to measure IL-8 displacement from heparin  
The test performed was a modified version of the classic competitive ELISA. Streptavidin (30 
g/mL, Sigma Aldrich, USA) was used to coat a Maxibinding 96-well plate (SPL Lifesciences) 
overnight (4 ◦C). The plate was then incubated with heparin–biotin (0.1 mg/mL, Sigma 
Aldrich, USA) at room temperature, followed by blocking (2% BSA in DPBS overnight at 4 
◦C). The next step was the binding of 1.5 μg/mL IL-8 (Millipore, USA) to the plate, in the 
absence and presence of a heparin derivative ranging from 0 to 10 μM and subsequent 
incubation with a rabbit anti-human IL8 primary (Millipore, Bedford, MA) (1:500, 50 L, 1 h) 
and a goat anti-rabbit-HRP-conjugated secondary (Millipore, Bedford, MA) (1:1000, 50 μL, 1 
h) antibody. All incubations were followed by triplicate washes in DPBS with the addition of 
0.05% Tween20. Finally, 0.4 mg/mL о-phenylenediamine (Sigma Aldrich, USA) in 50 mM 
citrate/dibasic sodium phosphate and 0.0004% hydrogen peroxide (Sigma Aldrich, USA) 
was added. The enzymatic reaction was terminated by addition of 1 M H2SO4. Absorbance 
measurements were made at 492 nm (VersaMaxmicroplate reader, Molecular Devices, 
USA). A calibration curve of IL-8 from 0 to 1.5 μg/mL was set up for each experiment. 
 
2.4. Elastase inhibition assays  
The inhibition test of human leukocyte elastase (EPC, Owensville, USA) was based on the 
release of ρ-nitroaniline from the chromogenic substrate MeO–Suc–Ala–Ala–Val–pNO2-
anilide (EPC, Owensville, USA). The reaction was conducted at 37 ◦C in 96- well plates and 
monitored by reading at 405 nm continuously for 25 min (VersaMaxmicroplate reader, 
Molecular Devices, USA). The substrate (240 μM final; 2.1 mM stock in phosphate buffer 50 
mM, pH 7.4, 15 mM DMSO, 0.13 M NaCl) was incubated for 10 min in the presence or 
absence of increasing concentrations of derivatives before adding the enzyme (60 nM; 800 
nM stock in sodium acetate 70 mM, pH 4.5). As control, the enzyme was inactivated with 
sulphuric acid (1 M, to a final concentration of 0.5 M) prior to the addition to the reaction mix. 
 
The ability of the derivatives to inhibit α-elastin digestion by human sputum elastase (EPC, 
Owensville, USA) was tested using a FastinTM Elastin kit (Biocolor, Carrickfergus, N. 
Ireland), employing an adaptation of the method recommended by the manufacturer. The 
modified procedure involved the digestion of a solution of α-elastin (20 μL, 1 mg/mL) in 50 
mM phosphate buffer pH 7.4 by elastase (100 μL final volume, 0.54 μM, 37 ◦C, 1 h) in the 
presence or absence of 0.54 M derivatives (1:1 molar ratio to elastase), inactivation with 
oxalic acid (1 M, to a final concentration of 0.25 M) and staining with the FastinTM kit, 
according to the manufacturer’s instruction. Briefly, α-elastin was precipitated using 50 μL of 
Precipitating Reagent and the tubes were then centrifuged (10,000 × g, 10 min). After the 
removal of the liquid, 500 μL of dye were added and the tubes were mixed (90 min, room 
temperature). After centrifugation and careful removal of the liquid, 250 μL of the Dye 
Dissociation Reagent were added. After mixing, the contents of the tubes were transferred to 
a 96-well plate and read at 513 nm (VersaMaxmicroplate reader, Molecular devices, USA). A 
calibration curve of α-elastin from 0 to 50 μg was obtained to verify the efficacy of the assay. 
As control, the enzyme was inactivated with oxalic acid (1 M, to a final concentration of 0.25 
M) prior to the addition of the substrate. 
 
2.5. Nuclear magnetic resonance  
The 13C NMR spectra of the heparin chemical derivatives (100 mg/mL) were recorded in D2O 
at 313K on Bruker AC300 and AMX400 spectrometers. The data were processed using 
Topspin 2.0 software. 
 
2.6. Circular dichroism  
The synchrotron radiation circular dichroism (SRCD) spectra were recorded (180 to 260 nm) 
on a purpose-built CD beam line (B23 at Diamond Light Source, Didcot, Oxfordshire, UK) 
using a CaF2 sample cell with 0.02 cm path length, employing 1 nm resolution. The slit 
widths for all spectra were 0.5 mm, 1 s integration time was used and the storage ring 
current was 250 mA for the duration of the experiments. SRCD spectra of the derivatives 
alone were also recorded (Supplementary data). Spectra of IL-8 were recorded at a 
concentration of 0.5 mg/mL in 17.5 mM phosphate buffer, the concentration of the 
derivatives were at equal weight ratios for all samples. TNF-α spectra were recorded at 10 
mg/mL, with 0.1 mg/mL derivatives, in 17.5 mM phosphate buffer. 
 
3. Results  
3.1. Preparation and characterisation of heparin derivatives  
A number of heparin derivatives were generated, based on a porcine mucosal heparin 
(PMH, compound 1) scaffold as described previously (Casu et al., 2004; Naggi et al., 2005). 
Heparin derivatives have been shown previously to exhibit strongly reduced anticoagulation 
activities, while maintaining the ability to interact with other proteins (Guimond, Turnbull, & 
Yates, 2006). Two series of compounds were produced for this study and compared; series 
A (1a-1c) and B (2 and 2a-2d). Both sets of compounds contained varying amounts of N-
acetylation. In series B, the non-sulfated uronate residues containing 2,3 vic-diols underwent 
periodate oxidation, forming a glycol-split uronic acid residue (Casu et al., 2004). 
Furthermore, prior to N-acetylation of compound 2b the sample was partially de-2-O-
sulfated, thereby providing a higher percentage of glycol-split uronic acids in this derivative. 
Scheme 1 contains the major repeating disaccharide unit of heparin and the structure of the 
glycol-split uronic acid. 
 
The compounds in series A and B are listed in Table 1. It should be noted that, as the 
degree of N-acetylation increases, the overall level of sulfation decreases, as expected. The 
degree of N-acetylation and periodate oxidation in the heparin compounds was quantified by 
13C NMR (see Supplementary data), while SEC–TDA was used to determine the weight 
average molecular weight of the compounds (Bertini et al., 2005). Size can be an influential 
parameter on the binding of polysaccharides to proteins, especially the minimum length that 
is required to establish an interaction. The molecular weight of the test compounds ranged 




Scheme 1 (A) The repeating disaccharide unit of the compounds comprising series A and B, based on R1 
and R2 = H/SO3−, R3 = SO3−/COCH3. The uronic acid in these compounds (derived from PIMH) is 
predominantly in the form l-iduronic acid (lIdoA and l-IdoA-2-O-sulfate; ∼ 80%) with d-glucuronic acid (d-
GlcA; ∼20%) making up the remainder. (B) Series B contains the glycol-split uronic acid residue (see 
Table 1 for full details of series A and B compounds). 
 
 
3.2. Neutrophil elastase inhibition  
Neutrophil elastase is a key enzyme involved in the excessive inflammation response, for 
example, in the lungs of CF patients. The ability of heparin derivatives to inhibit elastase was 
measured using two assays. The first involved measuring the release of - nitroaniline from a 
low molecular weight chromogenic substrate following the cleavage by human leukocyte 
elastase. The ability of the heparin derivatives to inhibit this enzyme is shown for 1a–1c in 
Fig. 1A and for 2a–2d in Fig. 1B. 
 
The second involved measurement of the inhibition of digestion of α-elastin by human 
leukocyte elastase by 1a–1c, shown in Fig. 1C and for 2a–2d shown in Fig. 1D. All heparin 
derivatives proved able to inhibit digestion of the synthetic peptide, similar to standard 
heparin, 1, at concentrations above 20 nM, while only minor differences were observed at 
lower concentrations, probably due to different modes of interaction. The glycol-split 
modification had no effect in either of the assays. The inhibitory effect of 1a–1c increased 
with the degree of N-acetylation using the peptide substrate, but no significant differences 
were found when α-elastin was used. Elastase inhibition was only partial, however; neither a 
3–4 fold increase in the concentration of heparin (up to 200 nM, data not shown) nor any of 
the derivatives proved able to inhibit the enzyme completely. The activities of the series A 
and B compounds are summarised in Table 2. The anticoagulant activities (anti-factor Xa, 
APTT, PT) and the major potential side-effects of heparin derivatives are shown, together 
with values for the inhibition of HLE and IL-8 displacement. The aPTT and PTT results 




Figure 1 Inhibition of human leukocyte elastase by heparin derivatives in assays measuring release of -
nitroaniline from a chromogenic peptide substrate, (A) (1a–1c) and (B) (2a–2d). The increase in 
absorbance at 513 nm reports the inhibition of digestion of the natural substrate (-elastin), (C) 
(compounds 1, 1a–1c) and (D) (compounds 2, 2a–2d). The negative control is the level of digestion in the 
presence of inactive enzyme, while the positive control is the digestion in the absence of inhibitors. 
Results shown are averages of 3 independent experiments, each with 2 replicates, ± standard errors. 
Error bars on the negative controls are negligible. 
 
decrease of sulfation degree, while the glycol-split modification, whilst present in only 25–
35% of disaccharides, abolished the anticoagulant activities. 
 
3.3. Anticoagulant activity screening using anti-factor Xa, APTT and PT 
assays  
The major potential side-effect associated with heparin derivatives relates to their ability to 
interfere with the blood clotting cascade, via interactions with a number of proteins. The 
best-known activity of intact heparin, which is exploited in its application as a pharmaceutical 
anticoagulant, involves an interaction with antithrombin and subsequently with factor Xa, the 
region of the clotting cascade termed the common pathway. However, there are several 
other points in the clotting cascade, at which heparin derivatives can also exert influence. 
These activities occur in two branches, one termed the extrinsic (tissue factor) pathway and 
the other the intrinsic (contact activation) pathway. These activities can be measured 
conveniently by straightforward assays, using the prothrombin time (PT) and the activated 
prothrombin time (APTT), respectively, in addition to the antithrombin activity of the common 
pathway (anti-factor Xa assay). The results of these three assays for 1a–1c and 2–2d, are 
shown in Table 2. 
 
3.4. Interaction with interleukin-8  
The ability of the heparin derivatives to interact with IL-8, a key modulator of inflammation, 
was also tested by two independent methods. The first measured their ability to displace IL-8  
Table 2 Anticoagulant properties and the percentage inhibition of HLE for compound series A and B. The 
table contains, from left to right, anticoagulant (percentage factor Xa inhibition), activated partial 
thromboplastin time (APTT), prothrombin time (PT) and inhibition of elastase (chromogenic peptide 
method and elastin assay) for heparin and its chemical derivatives. 
Series Compound % Factor 
Xa 
inhibition 








A 1 (PMH) 79.6 1.0 2.0 30.0 35 
 1a 24.1 4.0 2.5 19.0 48** 
 1b 22.4 2.0 3.0 26.0 46** 
 1c 6.0 27.3 14.7 32.4 42* 
B 2 17.0 8.7 9.1 22.6 39 
 2a 10.5 7.3 91.2 22.7 41* 
 2b 12.8 15.2 90.8 27.7 28 
 2c 11.0 178.8 237.0 24.0 41* 
 2d 13.5 264.0 >237 25.6 39* 
§ Reported values are normalised relative to control heparin (1), which had APTT and PT activities (EC50) of 2.1 
and 23.9 μg/mL. Higher values denote a weaker anticoagulant activity than heparin.  
# The percentage reported is relative to a specific concentration of the compounds as indicated in the headings 
of each column, for a range of concentrations see Fig. 1.  
◊ Comparison with positive control (absence of inhibitor): one way ANOVA—Dunnett’s multiple comparison test (* 
p < 0.05, ** p < 0.01). 
 
 
in solution from surface-bound heparin using a competitive ELISA (Fig. 2A and B). While, the 
second monitored direct binding in solution to IL-8 through changes in IL-8 protein 
secondary structure, detected via chiral chromophores present in the protein backbone 
which are sensitive to conformational changes when probed using synchrotron radiation 
circular dichroism (SRCD) spectroscopy (Fig. 3). 
 
 
Figure 2 Competitive ELISA showing displacement of bound IL-8 from surface immobilised heparin by 
1a–1c (A) and 2a–2d (B). Reference heparin 1 is shown on both graphs. 
 
 
All of the heparin derivatives were able to compete with heparin for IL-8 binding and were, 
therefore, able to displace it. Several were more active than the reference heparin (1), which 
was able to displace less than 50%, before reaching a plateau. In series A, 1a promoted a 
more effective displacement up to almost 90% and in a different manner to both 1 and 1b or 
1c, suggesting distinct modes of interaction. The differences between 1b and 1c, 2 and 2b 
were not statistically significant. The glycol-split modification of heparin 2 did not improve its  
 
Figure 3 . (A) Interaction of heparin and derivatives in solution with IL-8 demonstrated through changes 
in protein secondary structure. SRCD spectra (185–260 nm) of IL-8 in the presence of selected test 
compounds (1a, 1c, 2d), unmodified porcine mucosal heparin (1) and the natural ligand heparan sulfate 
(HS) in a 1:1 molar ratio. The spectra of heparin and derivatives alone were subtracted. (B) SRCD spectra 
(185–260 nm) of TNF-α in the presence of heparin derivatives 1a, 1c, 2d and unmodified porcine mucosal 
heparin 1, which induces changes in the secondary structure of the protein, demonstrating a direct 
interaction in solution. 
 
ability to compete with the standard heparin bound to the plate, although a concentration-
dependent effect was observed, distinct from that observed for unmodified heparin (1). 
Compound 2b was less efficient than the N-acetylated counterpart in detaching IL-8, in 
contrast to compounds 2c and 2d. Synchrotron radiation circular dichroism spectroscopy in 
the range 185–260 nm, which is sensitive to secondary structure changes in proteins, was 
used to establish, unequivocally, the interaction between IL-8 and heparin derivatives in 
solution. Profound structural changes in IL-8 were observed in the presence of both standard 
heparin and selected derivatives (Fig. 3). The CD spectrum of IL-8 (Fig. 3) resembles that of 
a previously reported spectrum of IL-8 (amino acids 1–66) (Fernando, Nagle, & 
Rajarathnam, 2007). The two minima located at ∼204 and ∼224 nm are characteristic of the 
chemokine as a monomer (Fernando et al., 2007). The addition of the heparin derivatives, in 
molar ratio of ∼1:1, to IL-8 caused structural rearrangement of the protein, with the resulting 
spectra resembling that of a protein with a random-coil structure. 
 
3.5. Interaction of heparin derivatives with TNF-α˛, detected in solution 
by SRCD  
The interaction of selected heparin derivatives with TNF-α, which is involved in the 
inflammatory response, was also explored in solution. The SRCD spectra of TNF-α, alone, 
and in the presence of either unmodified heparin (1), or heparin derivatives 1a, 1c and 2d, 
which all exhibit favourable IL-8 binding and elastase inhibition are shown in Fig. 3. 
 
The TNF-α active form is a 51 kDa trimer held together by non-covalent interactions and its 
secondary structure comprises predominantly β-sheet and turns as evinced by the positive 
peak at 205 nm and a negative peak between 216 and 225 nm, although little α-helix is 
present. These data are consistent with previous CD and IR studies indicating that TNF-α 
contains about 60% β-sheet or turns and a significant amount of irregular structures (Eck & 
Sprang, 1989; Jones, Stuart, & Walker, 1989; Narhi et al., 1996). Binding of both standard 
heparin and derivatives, although present only in a 1:10 molar ratio, caused significant and 
distinct changes in the CD spectra of TNF-α but, while 1 caused a 40% increase in β-sheet, 
its derivatives influenced the secondary structure of the protein in different ways. 
 
4. Discussion  
The chemical modification of heparin can generate compounds with a wide-range of 
activities, some of which depend on their overall charge but, more often, exhibit subtle 
variation as a function of substitution pattern. To help allay fears that any desirable activities 
were dependent only on charge density, two series of chemically modified heparin 
derivatives were compared. 
 
The principal anticoagulant activity of heparin, through activation of antithrombin and 
inhibition of factor Xa, can be measured readily, enabling derivatives to be screened. Highly 
charged polysaccharides, generated either by deliberate modification, or introduced through 
adulteration, can activate the extrinsic (tissue factor) or intrinsic (contact activation) 
pathways, causing further unwanted coagulation (Guerrini et al., 2008;Kishimoto et al., 
2008). The glycol-split modification of N-acetylated compounds, 2a–2d, resulted in reduction 
of the anticoagulation activity (Table 2), demonstrating that this type of modification can be 
useful to reduce undesired side effects without altering the substitution pattern of heparin. 
For example, 1c and 2d contain the same level of N-acetylation, but 2d showed much lower 
anticoagulant activity than 1c, and this trend obtains for all glycol-split compounds. 
 
Compounds were screened for their ability to inhibit neutrophil elastase. From these two 
series of derivatives, the most promising are 1c from series A, and both 2c and 2d from 
series B, that inhibit NE and exhibit anticoagulant activity more than 10 times lower than 
heparin. Although the inhibition level did not exceed 50%, complete inhibition of elastase 
activity may impair the ability to combat bacterial infection, while significant attenuation of its 
activity is desirable. 
 
Compounds from both series were able to bind and displace IL-8 from the surface of the 
ELISA plate (Fig. 2A and B) and interaction was confirmed in solution independently using 
SRCD (Fig. 3). It is apparent from the SRCD spectra of IL-8 with the modified 
polysaccharides, that each derivative induces distinct structural changes in IL-8, implying 
either distinct binding modes, the induction of different structural changes by distinct 
structures binding the same binding site, or a mixture of both. The ELISA results (Fig. 2A 
and B) showed that 1a was able to displace up to 90% of IL-8 from the plate at 3.3 μM, while 
its glycol-split counterpart, 2b, despite increased structural flexibility (Casu et al., 2002), was 
a less effective inhibitor. In contrast, the glycol-split modification of 1c increased the affinity 
for IL-8. From another perspective, with the exception of 2b in which partial 2-O desulfation 
did not promote further activity, the increase of N-acetylation in glycol-split compounds 
promoted affinity for IL-8, suggesting that factors besides pure electrostatics were 
responsible for the interaction (Rudd et al., 2010). 
 
The interaction of IL-8 with intact heparin has been mapped, and involves the C-terminal -
helix and residues 18–23, including a lysine at position 20 (Kuschert et al., 1998) while 
several other lysine residues were identified as critical, including K64 and R68 and the IL-8 
sequence contains others with which heparin derivatives may interact, including at positions 
20, 60 and 67. It is also known that removal of sulfates can have dramatic effects on the 
conformation of heparin derivatives, affecting both glycosidic linkage geometry and uronate 
residue conformations (Rudd et al., 2007). It is noteworthy that, while the compounds 
showed lowered anticoagulant activity as a consequence of the structural modifications 
made, which reduced their overall charge, they still retained the desired target activities, 
some comparable to, or better than, unmodified heparin (Figs. 1 and 2 and Table 2). Many 
heparin chemical derivatives have been studied and characterised and some of their 
activities, such as angiogenesis inhibition, anti-metastatic activity and antagonism of P-
selectins, have been recorded. Particularly, the glycol-split heparin derivatives, with various 
levels of N-acetylation, have previously been reported to inhibit P-selectin and heparanase, 
which are also involved in inflammation (Borsig et al., 2001; Naggi et al., 2005). The results 
presented here suggest that compounds with moderate levels of N-acetylation and glycol 
split (e.g. 2a and 2c) could also retain the ability to inhibit heparanase, as well as binding IL-
8. 
 
Given that unmodified heparin is known to interact with several hundred proteins (Ori et al., 
2008), many of them involved in cell signalling and regulation, it is perhaps surprising that 
heparin administration does not elicit more side-effects in patients undergoing anticoagulant 
therapy (Cestac et al., 2003; Quinlan et al., 2012). While this is encouraging for those aiming 
to develop alternative treatments employing a heparin scaffold, it does present something of 
a puzzle, and the explanation may lie in the interconnected nature of these signalling and 
regulatory systems. For example, in recent work on the FGF–FGFR signalling system, 
analysed in terms of the effects of intact heparin, it has been observed that a very well-
connected and highly redundant signalling system exists (Xu et al., 2013). This robustness 
may be a characteristic of such highly connected networks (of which the inflammation 
response is another example (Calvano et al., 2005)). Binding by heparin to several proteins 
in the network may simply result in a strongly dampened effect throughout. Reducing the 
sulfation level of derivatives, which can also have the overall effect of lowering the 
heterogeneity of the heparin, may focus some of these activities into fewer interactions, 
resulting in higher selectivity, hence provide agents with distinct activities, yet capable of 
effective intervention. 
 
Significant structural changes in TNF- upon binding to heparin and derivatives (1a) (Fig. 3) 
were observed using SRCD. It is also possible that other proteins involved in the 
inflammatory response interact with, and are affected by, these compounds. Key players 
such as P-selectin (O’Sullivan et al., 2005), whose dependent cell rolling in the vascular 
lumen is prevented by heparin (Borsig et al., 2001), or L-selectin, whose effects are also 
inhibited by heparin (Hostettler et al., 2007; Koenig, Norgard-Sumnicht, Linhardt, & Varki, 
1998), metalloproteases (Morishima et al., 2001; Warner et al., 2004) and other interleukins 
are obvious candidates to investigate. 
 
5. Conclusions  
The heparin derivatives prepared here interacted with IL-8 and TNF-α and partially inhibited 
cleavage of both a synthetic peptide and a natural substrate by human sputum elastase in 
vitro. The partial, rather than the complete inhibition of key elements involved in the 
excessive inflammation response could return the immune response towards normal levels, 
thereby reducing damage to lung tissue, while maintaining some capacity to combat 
infection. The compounds identified offer a starting point for future drug development, 
opening-up the possibility of the synthesis of polysaccharides or analogues with lower 
molecular weight, capable of acting on multiple cytokines with the ability to decrease 
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